|
2024 Journal Article Characterization of Wearable Respiratory Sensors for Breathing Parameter MeasurementsSabz, Mozhgan, MacLean, Joanna, Martin, Andrew R. and Rouhani, Hossein (2024). Characterization of Wearable Respiratory Sensors for Breathing Parameter Measurements. IEEE Sensors Journal, 24 (20), 32283-32290. doi: 10.1109/jsen.2024.3448539 |
|
2024 Journal Article Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation frameworkCho, Doah, Lord, Sarah J., Ward, Robyn, IJzerman, Maarten, Mitchell, Andrew, Thomas, David M., Cheyne, Saskia, Martin, Andrew, Morton, Rachael L., Simes, John and Lee, Chee Khoon (2024). Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework. Therapeutic Advances in Medical Oncology, 16, 1-20. doi: 10.1177/17588359241273062 |
|
2024 Journal Article Colorectal cancer survivors' experiences and views of shared and telehealth models of survivorship care: a qualitative studyGore, Claire, Lisy, Karolina, O’Callaghan, Clare, Wood, Colin, Emery, Jon, Martin, Andrew, De Abreu Lourenco, Richard, Schofield, Penelope and Jefford, Michael (2024). Colorectal cancer survivors' experiences and views of shared and telehealth models of survivorship care: a qualitative study. Psycho-Oncology, 33 (1) e6265. doi: 10.1002/pon.6265 |
|
2024 Journal Article Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialHofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R., Williams, Scott G. ... Yip, Sonia (2024). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. The Lancet Oncology, 25 (1), 99-107. doi: 10.1016/s1470-2045(23)00529-6 |
|
2023 Journal Article Accuracy of oncologists' estimates of expected survival time in advanced cancerNahm, Sharon H., Martin, Andrew J., Clayton, Josephine M., Grimison, Peter, Moth, Erin B., Pavlakis, Nick, Sjoquist, Katrin, Smith-Uffen, Megan E. S., Tognela, Annette, Vasista, Anuradha, Stockler, Martin R. and Kiely, Belinda E. (2023). Accuracy of oncologists' estimates of expected survival time in advanced cancer. JNCI Cancer Spectrum, 7 (6) pkad094. doi: 10.1093/jncics/pkad094 |
|
2023 Journal Article SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancerJefford, Michael, Emery, Jon D., James Martin, Andrew, De Abreu Lourenco, Richard, Lisy, Karolina, Grunfeld, Eva, Mohamed, Mustafa Abdi, King, Dorothy, Tebbutt, Niall C., Lee, Margaret, Mehrnejad, Ashkan, Burgess, Adele, Marker, Julie, Eggins, Renee, Carrello, Joseph, Thomas, Hayley and Schofield, Penelope (2023). SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancer. eClinicalMedicine, 66 102346, 1-11. doi: 10.1016/j.eclinm.2023.102346 |
|
2023 Journal Article Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancerSjoquist, Katrin M., Martin, Andrew, Pavlakis, Nick, Goldstein, David, Tsobanis, Eric, Moses, Daniel, Maher, Richard, Hague, Wendy, Gebski, Val, Stockler, Martin R. and Simes, R. John (2023). Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. Journal of Cancer Research and Clinical Oncology, 149 (8), 4959-4965. doi: 10.1007/s00432-022-04404-4 |
|
2023 Journal Article Nicotinamide for Skin-Cancer Chemoprevention in Transplantation. ReplyAllen, Nicholas C., Martin, Andrew J. and Damian, Diona L. (2023). Nicotinamide for Skin-Cancer Chemoprevention in Transplantation. Reply. The New England journal of medicine, 388 (26), 2494-2495. doi: 10.1056/NEJMc2303841 |
|
2023 Journal Article Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialSweeney, Christopher J, Martin, Andrew J, Stockler, Martin R, Begbie, Stephen, Cheung, Leanna, Chi, Kim N, Chowdhury, Simon, Frydenberg, Mark, Horvath, Lisa G, Joshua, Anthony M, Lawrence, Nicola J, Marx, Gavin, McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A, Parnis, Francis, Parulekar, Wendy, Pook, David W, Reaume, Martin Neil, Sandhu, Shahneen K, Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Vera-Badillo, Francisco, Williams, Scott G, Winter, Diana, Yip, Sonia, Zhang, Alison Y ... Thomas, Carys (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. The Lancet Oncology, 24 (4), 323-334. doi: 10.1016/S1470-2045(23)00063-3 |
|
2023 Journal Article Nicotinamide for skin-cancer chemoprevention in transplant recipientsAllen, Nicholas C., Martin, Andrew J., Snaidr, Victoria A., Eggins, Renee, Chong, Alvin H., Fernandéz-Peñas, Pablo, Gin, Douglas, Sidhu, Shireen, Paddon, Vanessa L., Banney, Leith A., Lim, Adrian, Upjohn, Edward, Schaider, Helmut, Ganhewa, Aparna D., Nguyen, Jennifer, Mckenzie, Catriona A., Prakash, Saurabh, Mclean, Catriona, Lochhead, Alistair, Ibbetson, Jan, Dettrick, Andrew, Landgren, Anthony, Allnutt, Katherine J., Allison, Clare, Davenport, Rachael B., Mumford, Blake P., Wong, Brittany, Stagg, Brendan, Tedman, Alexander ... Damian, Diona L. (2023). Nicotinamide for skin-cancer chemoprevention in transplant recipients. New England Journal of Medicine, 388 (9), 804-812. doi: 10.1056/NEJMoa2203086 |
|
2023 Journal Article INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)Lam, Lyn Ley, Pavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin M., Martin, Andrew J., Yip, Sonia, Kang, Yoon-Koo, Bang, Yung-Jue, Chen, Li-Tzong, Moehler, Markus, Bekaii-Saab, Tanios, Alcindor, Thierry, O’Callaghan, Christopher J., Tebbutt, Niall C., Hague, Wendy, Chan, Howard, Rha, Sun Young, Lee, Keun-Wook, Gebski, Val, Jaworski, Anthony, Zalcberg, John, Price, Timothy, Simes, John and Goldstein, David (2023). INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). BMC Cancer, 23 (1) 180, 1-12. doi: 10.1186/s12885-023-10642-7 |
|
2023 Journal Article Evaluation of 177Lu-PSMA SPECT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN)Pathmanandavel, Sarennya, Crumbaker, Megan, Ho, Bao, Yam, Andrew O., Wilson, Peter, Niman, Remy, Ayers, Maria, Sharma, Shikha, Hickey, Adam, Eu, Peter, Stockler, Martin, Martin, Andrew J., Joshua, Anthony M., Nguyen, Andrew and Emmett, Louise (2023). Evaluation of 177Lu-PSMA SPECT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN). Journal of Nuclear Medicine, 64 (2), 221-226. doi: 10.2967/jnumed.122.264398 |
|
2023 Journal Article Nicotinamide for Skin-Cancer Chemoprevention in TransplantationSchmults, Chrysalyne D., Jambusaria-Pahlajani, Anokhi, Ruiz, Emily, Trepanowski, Nicole, Kim, Daniel Y., Hartman, Rebecca I., Allen, Nicholas C., Martin, Andrew J. and Damian, Diona L. (2023). Nicotinamide for Skin-Cancer Chemoprevention in Transplantation. New England Journal of Medicine, 388 (26), 2493-2495. doi: 10.1056/NEJMc2303841 |
|
2023 Journal Article The prognostic value of posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 and NOX66 in a phase I/II trial (LuPIN)Pathmanandavel, Sarennya, Crumbaker, Megan, Nguyen, Andrew, Yam, Andrew O., Wilson, Peter, Niman, Remy, Ayers, Maria, Sharma, Shikha, Eu, Peter, Martin, Andrew J., Stockler, Martin R., Joshua, Anthony M. and Emmett, Louise (2023). The prognostic value of posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 and NOX66 in a phase I/II trial (LuPIN). Journal of Nuclear Medicine, 64 (1), 69-74. doi: 10.2967/jnumed.122.264104 |
|
2022 Journal Article Estimation of the treatment effect following a clinical trial that stopped early for benefitMarschner, Ian C., Schou, Manjula and Martin, Andrew J. (2022). Estimation of the treatment effect following a clinical trial that stopped early for benefit. Statistical Methods in Medical Research, 31 (12), 2456-2469. doi: 10.1177/09622802221122445 |
|
2022 Journal Article Changes to design and analysis elements of research plans during randomised controlled trials in AustraliaCoskinas, Xanthi, Simes, R. John and Martin, Andrew J. (2022). Changes to design and analysis elements of research plans during randomised controlled trials in Australia. Medical Journal of Australia, 217 (10), 526-531. doi: 10.5694/mja2.51715 |
|
2022 Journal Article PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trialButeau, James P, Martin, Andrew J, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen, Joshua, Anthony M, Francis, Roslyn J, Zhang, Alison Y, Scott, Andrew M, Lee, Sze-Ting, Azad, Arun A, McJannett, Margaret M, Stockler, Martin R, Williams, Scott G, Davis, Ian D, Hofman, Michael S, Akhurst, Tim, Alipour, Ramin, Banks, Patricia, Beaulieu, Alexis, Chua, Wei, Dhiantravan, Nattakorn, Ford, Kate, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J ... for the TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2022). PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. The Lancet Oncology, 23 (11), 1389-1397. doi: 10.1016/S1470-2045(22)00605-2 |
|
2022 Journal Article Hierarchical improvement of regional tissue oxygenation after packed red blood cell transfusionBalegar, Kiran Kumar V., Jayawardhana, Madhuka, Martin, Andrew J., de Chazal, Philip and Nanan, Ralph Kay Heinrich (2022). Hierarchical improvement of regional tissue oxygenation after packed red blood cell transfusion. PLoS One, 17 (7 July) e0271563, 7. doi: 10.1371/journal.pone.0271563 |
|
2022 Journal Article Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionalsNahm, Sharon H., Stockler, Martin R., Martin, Andrew J., Grimison, Peter, Fox, Peter, Zielinski, Rob, Hawson, Geoffrey At., Tattersall, Martin Hn. and Kiely, Belinda E. (2022). Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals. Supportive Care in Cancer, 30 (9), 7763-7772. doi: 10.1007/s00520-022-07167-3 |
|
2022 Journal Article ‘Pain-free TRUS B’: a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)Hayne, Dickon, Grummet, Jeremy, Espinoza, David, McCombie, Steve P., Chalasani, Venu, Ford, Kate S., Frydenberg, Mark, Gilling, Peter, Gordon, Barbara, Hawks, Cynthia, Konstantatos, Alex, Martin, Andrew J., Nixon, Anthony, O’Brien, Colin, Patel, Manish I., Sengupta, Shomik, Shahbaz, Shekib, Subramaniam, Shalini, Williams, Scott, Woo, Henry H., Stockler, Martin R., Davis, Ian D. and Buchan, Nick (2022). ‘Pain-free TRUS B’: a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501). BJU International, 129 (5), 591-600. doi: 10.1111/bju.15552 |
